The estimated Net Worth of Tim Ocain is at least $97.8 Thousand dollars as of 3 December 2018. Tim Ocain owns over 2,000 units of Enanta Pharmaceuticals Inc stock worth over $97,849 and over the last 11 years Tim sold ENTA stock worth over $0.
Tim has made over 2 trades of the Enanta Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Tim exercised 2,000 units of ENTA stock worth $64,540 on 3 December 2018.
The largest trade Tim's ever made was exercising 25,000 units of Enanta Pharmaceuticals Inc stock on 1 October 2018 worth over $622,500. On average, Tim trades about 2,250 units every 5 days since 2014. As of 3 December 2018 Tim still owns at least 8,127 units of Enanta Pharmaceuticals Inc stock.
You can see the complete history of Tim Ocain stock trades at the bottom of the page.
Tim's mailing address filed with the SEC is C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN, MA, 02472.
Over the last 11 years, insiders at Enanta Pharmaceuticals Inc have traded over $72,640,961 worth of Enanta Pharmaceuticals Inc stock and bought 354,891 units worth $5,071,651 . The most active insiders traders include Jay R. Luly, V Life Science Ventures Gmb..., and Yat Sun Or. On average, Enanta Pharmaceuticals Inc executives and independent directors trade stock every 26 days with the average trade being worth of $285,155. The most recent stock trade was executed by Scott T. Rottinghaus on 11 July 2024, trading 11,945 units of ENTA stock currently worth $190,762.
enanta pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis c virus (hcv). these inhibitors include members of the direct acting antiviral (daa) inhibitor classes – protease (partnered with abbvie), ns5a, and nucleotide polymerase – as well as a host-targeted antiviral (hta) inhibitor class targeted against cyclophilin. enanta’s lead protease inhibitor, paritaprevir, is part of abbvie’s recently approved hcv treatment regimen. in addition, enanta has a preclinical program in non-alcoholic steatohepatitis, or nash, which is a condition that results in liver inflammation and damage caused by a buildup of fat in the liver. enanta pharmaceuticals is a public company with offices in watertown, ma.
Enanta Pharmaceuticals Inc executives and other stock owners filed with the SEC include: